ClinicalTrials.gg
CompletedNCT02568904Updated May 15, 2020

Alcohol and Innate Immunity

An observational study in Binge Drinking, sponsored by Medical University of Graz. Completed at 1 site in Austria. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-15.

Sponsored by Medical University of Graz · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
46
Ages
18 Years to 99 Years
Sex
All
01

Study summary

Alcohol leads to a leaky gut and translocation of bacterial products. This may lead to inflammation and immune dysfunction as well as the typical hangover symptoms.

Read the detailed description

Alcohol binge drinking, defined as 5 or more drinks for men and 4 or more drinks for women at one time, is the most frequent form of alcohol consumption worldwide, especially in younger people. This drinking pattern is popular and leads to increased mortality and morbidity. Therefore binge drinking is a major public health issue. The behavioural and neurological consequences of binge drinking are well characterized.

Less is known about the systemic effects on the gut as the first organ in contact with alcohol. Chronic alcohol intake can lead to increased gut permeability, bacterial translocation and alterations in the gut microbiome in animal models. Recently bacterial translocation has been shown in healthy volunteers after a single alcohol binge. On immune cells, acute alcohol intake seems to have dichotomous effects. On the one hand immunosuppressive and anti-inflammatory effects have been described, however, alcohol induced liver injury is driven by pro-inflammatory reactions. These immune effects seem to be driven by endotoxin or other bacterial products via Toll-like receptors that are translocated to the circulation via a defective gut barrier. Immune effects of alcohol have also been linked to hangover symptoms after an alcohol binge.

Furthermore there is evidence that endotoxemia might also contributes to alcohol dependence by promoting prolonged and increased voluntary alcohol intake in mice. On the other hand mutant mice lacking important genes for immune responses exhibit decreased alcohol consumption. This indicates that immune signaling promotes alcohol consumption. Therefore it is tempting to speculate that increased gut permeability leading to increased bacterial translocation after an acute alcohol binge could promote the desire for further alcohol consumption.

The investigators aim to test in this pilot trial whether one alcohol binge damages gut barrier function, increases bacterial translocation and causes innate immune dysfunction. Furthermore the effect of glucose and fructose will be studied too.

02

Conditions studied

  • Binge Drinking

Browse trials for

03

In context

Binge Drinking

71 studies on the registry are indexed under Binge Drinking; 20 are open to participants now.

Browse Binge Drinking studies →

Lead sponsor

Medical University of Graz is the lead sponsor of 471 studies on the registry; 98 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Healthy volunteers selected from a database

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to give for participation in the study.
  • Age above 18 years
  • Willingness to abstain from alcohol 48h prior to the study visits

Exclusion criteria

Exclusion Criteria:

  • Alcohol abuse .Alcohol Use Disorders Identification Test ≥ 8 in men or ≥ 7 in women or CAGE test ≥ 2 (both men and women)
  • Elevated liver function test
  • Any disease or medication that does not allow concomitant consumption of alcohol
  • Women: pregnancy and lactation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
46 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Alcohol binge

    Healthy volunteers receive 2ml vodka 40% per kg bodyweight as a binge

    Other: Alcohol

  • Fructose

    75 g Fructose orally

    Other: Fructose

  • Glucose

    75 g Glucose orally

    Other: Glucose

  • Vehicle

    2ml tap water per kg body weight

    Other: vehicle

Interventions

  • OtherAlcohol

    every participant will drink vodka at a dose of 2ml/kg bodyweight

  • OtherGlucose

    oral Glucose tolerance test

  • OtherFructose

    oral fructose tolerance test

  • Othervehicle

    control (water)

06

What researchers measure

Primary outcomes

  1. Endotoxin assessed by percentage of endotoxin positive subjects

    Endotoxin measured by a HEK-blue cell based assay

    Time frame: 4 hours

Secondary outcomes

  1. gut permeability (zonulin in stool)

    changes in gut permeability

    Time frame: 4 hours

  2. bacterial translocation (bacterial DNA in serum)

    changes in bacterial translocation

    Time frame: 4 hours

  3. oxidative stress (advanced oxidation protein products)

    changes in oxidative stress

    Time frame: 4 hours

  4. inflammation (neutrophil oxidative burst)

    changes in inflammation

    Time frame: 4 hours

  5. neutrophil phagocytic capacity

    changes in neutrophil function

    Time frame: 4 hours

  6. gut microbiome composition

    changes in gut microbiome composition

    Time frame: 4 hours

  7. fibroblast growth factor 21 (FGF21)

    changes in FGF21 serum levels

    Time frame: 4 hours

07

Study locations

1 site
  • Department of Internal Medicine, Medical University of Graz
    Graz, 8010, Austria
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Feb 2019, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2015
First posted
Oct 6, 2015
StartActual
Dec 2016
Primary completionActual
Feb 22, 2019
CompletionActual
Feb 22, 2019
Last update
May 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02568904
Responsible party
Sponsor
First posted
Oct 6, 2015
Start date
Dec 2016
Primary completion
Feb 22, 2019
Completion
Feb 22, 2019
Last update
May 15, 2020

Study contacts

Vanessa Stadlbauer, MD
principal investigator · Medical University of Graz

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion